DigitalOcean Holdings Inc vs GeneDx Holdings Corp — how do they compare? DigitalOcean Holdings Inc trades at $126.65 (market cap $14.57B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: DigitalOcean Holdings Inc is far larger — about 7.2× GeneDx Holdings Corp's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and GeneDx Holdings Corp for 19 Days on average.
| DOCN | WGS | |
|---|---|---|
Market Cap | $14.57B | $2.02B |
Volume | 2,261,786 | 734,640 |
Sector | Technology | Health |
52-Week High | $181.29 | $167.51 |
52-Week Low | $37.30 | $34.51 |
Typical Hold Time | 43 Days | 19 Days |
Enterprise Value | $15.33B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong technical support at $126 and resistance at $130. The company shows robust revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive to $259M. Recent AI-focused product launches including Agent Droplets and Managed Agents position the company for continued growth in cloud services.
Despite high valuation multiples (P/E 57.85, P/S 14.34), analyst consensus remains bullish with a $172.73 price target representing 36% upside. Key risks include capital intensity from expansion and high debt levels, while institutional accumulation and consistent earnings beats support the growth narrative.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →